-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2024-06-26
BOX:F:F- (EUR)
COMMON STOCK | Medical Instruments & Supplies |
Last Closing
USD 217.7Change
-1.40 (-0.64)%Market Cap
USD 64.33BVolume
45.00Verdict
Verdict
Values as of: 2024-06-26
COMMON STOCK | Medical Instruments & Supplies |
Last Closing
USD 217.7Change
-1.40 (-0.64)%Market Cap
USD 64.33BVolume
45.00Verdict
Verdict
Currency: EUR
Country : Germany
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
IUI1:F | Intuitive Surgical Inc |
-1.05 (-0.25%) |
USD 143.32B |
ESL:F | EssilorLuxottica Société ano.. |
-1.80 (-0.88%) |
USD 95.80B |
ESLC:F | ESSILORLUXOTTICA 1/2/O.N. |
-2.00 (-1.96%) |
USD 93.89B |
HYB0:F | HOYA CORP. ADR/ 1 O.N. |
N/A |
USD 38.45B |
HYB:F | HOYA Corporation |
-0.35 (-0.32%) |
USD 38.30B |
RME:F | ResMed Inc |
+3.50 (+1.97%) |
USD 26.35B |
CBH:F | COLOPLAST SP.ADR 1/10 DK1 |
-0.10 (-0.92%) |
USD 25.53B |
CBHD:F | Coloplast A/S |
-1.00 (-0.88%) |
USD 25.50B |
RMEA:F | Resmed Inc DRC |
+0.20 (+1.14%) |
USD 25.27B |
TUO:F | Terumo Corporation |
N/A |
USD 22.79B |
N/A
Market Performance vs. Industry/Classification (Medical Instruments & Supplies) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | -1.05% | 60% | D- | 47% | F | ||
Dividend Return | 0.86% | 40% | F | 15% | F | ||
Total Return | -0.18% | 55% | F | 43% | F | ||
Trailing 12 Months | |||||||
Capital Gain | -7.36% | 58% | F | 40% | F | ||
Dividend Return | 1.60% | 43% | F | 15% | F | ||
Total Return | -5.76% | 53% | F | 37% | F | ||
Trailing 5 Years | |||||||
Capital Gain | -0.50% | 50% | F | 44% | F | ||
Dividend Return | 5.10% | 42% | F | 18% | F | ||
Total Return | 4.60% | 42% | F | 35% | F | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | 0.55% | 55% | F | 49% | F | ||
Dividend Return | 1.41% | 50% | F | 46% | F | ||
Total Return | 0.86% | 59% | D- | 32% | F | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 9.99% | 82% | B | 85% | B | ||
Risk Adjusted Return | 14.12% | 56% | F | 49% | F | ||
Market Capitalization | 64.33B | 97% | N/A | 97% | N/A |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.
The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.
The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
This stock has shown below median revenue growth in the previous 5 years compared to its sector